iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 4,820,000 shares, an increase of 92.0% from the September 15th total of 2,510,000 shares. Based on an average daily volume of 518,700 shares, the days-to-cover ratio is presently 9.3 days. Currently, 17.2% of the shares of the company are sold short.
iTeos Therapeutics Stock Up 9.7 %
Shares of ITOS opened at $9.95 on Friday. The company has a 50-day moving average price of $13.84 and a two-hundred day moving average price of $14.47. The stock has a market cap of $363.37 million, a price-to-earnings ratio of -3.32 and a beta of 1.36. iTeos Therapeutics has a 12 month low of $8.20 and a 12 month high of $18.75.
iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.86. The company had revenue of $35.00 million for the quarter, compared to the consensus estimate of $4.20 million. Equities research analysts expect that iTeos Therapeutics will post -3.64 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Research Report on iTeos Therapeutics
Institutional Investors Weigh In On iTeos Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in ITOS. Acadian Asset Management LLC acquired a new position in shares of iTeos Therapeutics in the 1st quarter worth approximately $3,337,000. Clearline Capital LP acquired a new position in iTeos Therapeutics in the second quarter worth $2,328,000. Candriam S.C.A. bought a new stake in shares of iTeos Therapeutics during the second quarter worth $7,558,000. Kennedy Capital Management LLC bought a new stake in shares of iTeos Therapeutics during the first quarter worth $1,988,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of iTeos Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after buying an additional 117,159 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.
iTeos Therapeutics Company Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Featured Stories
- Five stocks we like better than iTeos Therapeutics
- Consumer Staples Stocks, Explained
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- How to Calculate Return on Investment (ROI)
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- What is the Shanghai Stock Exchange Composite Index?
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.